Format

Send to

Choose Destination
Nat Med. 2018 Jul;24(7):908-922. doi: 10.1038/s41591-018-0104-9. Epub 2018 Jul 2.

Mechanisms of NAFLD development and therapeutic strategies.

Author information

1
Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. scott.friedman@mssm.edu.
2
Division of Gastroenterology and Hepatology, St. Louis University School of Medicine, St. Louis, MO, USA.
3
Division of Gastroenterology and Hepatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
4
Division of Gastroenterology, Virginia Commonwealth University, Richmond, VA, USA.

Abstract

There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum of liver abnormalities from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), has a variable course but can lead to cirrhosis and liver cancer. Here we review the pathogenic and clinical features of NAFLD, its major comorbidities, clinical progression and risk of complications and in vitro and animal models of NAFLD enabling refinement of therapeutic targets that can accelerate drug development. We also discuss evolving principles of clinical trial design to evaluate drug efficacy and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression.

PMID:
29967350
PMCID:
PMC6553468
DOI:
10.1038/s41591-018-0104-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center